tbuckley/cabot-search huggingface dataset:
Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma
Authors: Christopher J. Gibson, R. Coleman Lindsley, Vatche Tchekmedyian, Brenton G. Mar, Jiantao Shi, Siddhartha Jaiswal, Alysia Bosworth, Liton Francisco, Jianbo He, Anita Bansal, Elizabeth A. Morgan, Ann S. Lacasce, Arnold S. Freedman, David C. Fisher, Eric Jacobsen, Philippe Armand, Edwin P. Alyea, John Koreth, Vincent Ho, Robert J. Soiffer, Joseph H. Antin, Jerome Ritz, Sarah Nikiforow, Stephen J. Forman, Franziska Michor, Donna Neuberg, Ravi Bhatia, Smita Bhatia, Benjamin L. Ebert
Journal: Journal of Clinical Oncology (2017)

Purpose Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition characterized by somatic mutations in the blood of otherwise healthy adults. We hypothesized that in patients undergoing autologous stem-cell transplantation (ASCT) for lymphoma, CHIP at the time of ASCT would be associated with an increased risk of myelodysplastic syndrome and acute myeloid leukemia, collectively termed therapy-related myeloid neoplasm (TMN), and other adverse outcomes. Methods We performed whole-exome sequencing on pre- and post-ASCT samples from 12 patients who developed TMN after autologous transplantation for Hodgkin lymphoma or non-Hodgkin lymphoma and targeted sequencing on cryopreserved aliquots of autologous stem-cell products from 401 patients who underwent ASCT for non-Hodgkin lymphoma between 2003 and 2010. We assessed the effect of CHIP at the time of ASCT on subsequent outcomes, including TMN, cause-specific mortality, and overall survival. Results For six of 12 patients in the exome sequencing cohort, mutations found in the TMN specimen were also detectable in the pre-ASCT specimen. In the targeted sequencing cohort, 120 patients (29.9%) had CHIP at the time of ASCT, which was associated with an increased rate of TMN (10-year cumulative incidence, 14.1% v 4.3% for those with and without CHIP, respectively; P = .002). Patients with CHIP had significantly inferior overall survival compared with those without CHIP (10-year overall survival, 30.4% v 60.9%, respectively; P &lt; .001), including increased risk of death from TMN and cardiovascular disease. Conclusion In patients undergoing ASCT for lymphoma, CHIP at the time of transplantation is associated with inferior survival and increased risk of TMN.
Development and optimization of an in vitro cultivation protocol allows for isolation of Borrelia miyamotoi from patients with hard tick-borne relapsing fever
Authors: J. Koetsveld, N.M. Kolyasnikova, A. Wagemakers, M.G. Toporkova, D.S. Sarksyan, A. Oei, A.E. Platonov, J.W. Hovius
Journal: Clinical Microbiology and Infection (2017)
Clinical Characteristics and Outcomes in Patients with t(8;21) Acute Myeloid Leukemia in Japan.
Authors: Hiroto Narimatsu, Toshiya Yokozawa, Hiroatsu Iida, Motohiro Tsuzuki, Masaya Hayakawa, Takaaki Takeo, Masaki Iino, Takuji Ichihashi, Chiaki Kato, Akiyo Sawamoto, Hiroshi Sao, Masamitsu Yanada, Nobuhiko Emi, Hitoshi Kiyoi, Tetsushi Yamaguchi, Tomoki Naoe, Ritsuro Suzuki, Isamu Sugiura
Journal: Blood (2007)
Prediction of Molecular Response of Chronic Phase CML Patients by the EUTOS Score: Results of the Randomized CML-Study IV,
Authors: Susanne Saussele, Michael Lauseker, Verena Hoffmann, Ulrike Proetel, Benjamin Hanfstein, Gabriela M. Baerlocher, Dominik Heim, Gerhard Ehninger, Dieter K. Hossfeld, Hans-Jochem Kolb, Stefan W. Krause, Christoph Nerl, Hans Pralle, Joerg E. A. Schubert, Hermann Einsele, Matthias Hänel, Anthony D. Ho, Christiane Falge, Lothar Kanz, Andreas Neubauer, Michael Kneba, Frank Stegelmann, Michael Pfreundschuh, Cornelius F. Waller, Karsten Spiekermann, Susanne Schnittger, Markus Pfirrmann, Andreas Hochhaus, Jörg Hasford, Rüdiger Hehlmann, Martin C Müller
Journal: Blood (2011)
Rapid, ultrafiltration-based method for purification of monoclonal antibodies from hybridoma supernatents
Authors: Darshan K. Koticha, Peter J. Rapiejko
Journal: Cancer Research (2006)

Proc Amer Assoc Cancer Res, Volume 47, 2006

1997 

Monoclonal antibodies (mAB) continue to gain importance as therapeutic and diagnostic agents for many types of cancer. The process of screening hybridoma libraries for candidate mABs is both time consuming and labor intensive. Once a hybridoma cell line expressing a suitable mAB is established, a bench-scale purification methodology (e.g. 50-500 mL) must be developed to produce sufficient mAB for further characterization. A traditional method for purifying mABs involves clarification of the hybridoma supernatent by centrifugation, followed by an ammonium sulphate precipitation to concentrate the mABs. The precipitate is then recovered by centrifugation, resolubilized and desalted using equilibrium dialysis. After these steps, the mAB is further purified using Protein A/G affinity chromatography. The purified antibody is desalted and exchanged into a biological buffer using dialysis. The entire process typically requires several days to complete and can be particularly onerous if multiple mABs are to be evaluated in parallel. We describe a new and simplified method that minimizes the processing time to less than a day to obtain pure mAB. The method involves clarification of the hybridoma supernatent by microfiltration, followed by concentration using ultrafiltration. The mAB is further purified on Protein A/G beads. The purified mAB is desalted and buffer-exchanged using ultrafiltration. This approach was successfully used to purify an anti c-myc antibody secreted by the hybridoma clone 9E10 (Evan G, et al., 1985). The mAB purified by this new method performed comparably to the commercially purified mAB in downstream applications such as western blotting and immunofluorescence. The data demonstrate that the new protocol is robust and delivers mAB of a high purity and yield as compared to the traditionally purified mAB. The application of ultrafiltration to mAB purification will be of considerable value to any researcher interested in screening hybridoma libraries and accelerating the purification of mABs.
Outcome after Autologous Stem Cell Transplantation for Multiple Myeloma in Patients with Preceeding Plasma Cell Disorders.
Authors: Shaji Kumar, David Dingli, Angela Dispenzieri, Martha Q. Lacy, Suzanne R. Hayman, Francis K. Buadi, S. Vincent Rajkumar, Mark R. Litzow, Morie A. Gertz
Journal: Blood (2007)
A Specialized Polarized Membrane Domain Found On Normal but Not Leukemic Hematopoietic Progenitor Cells Is Required for Homing to the Bone Marrow Microenvironment.
Authors: Andre Larochelle, Jennifer Gillette, Amy Cantilena, Alexandra Cerf, Jennifer Lippincott-Schwartz, Cynthia E. Dunbar
Journal: Blood (2009)
Factor V G1691A and Factor II G20210A Mutations and Clinical Expression of Severe Hemophilia A (&amp;lt; 2%) in Children: Impact on Bleeding Episodes and Joint Damage.
Authors: Ulrike Nowak-Gottl, Carmen Escuriola, Rosemarie Schobess, Christine Duering, Christoph Bidlingmaier, Hartmut Pollmann, Sylvia Horneff, Karin Kurnik
Journal: Blood (2004)
Biological Activities of Two Ultra-Low Molecular Weight Heparins, Semuloparin and Bemiparin, Reveal That a Common Potency Standard Is Inadequate
Authors: Walter Jeske, Debra Hoppensteadt, Angel Gray, Jeanine M. Walenga, Josephine Cunanan, Lauren Myers, Jawed Fareed, Helene Rigal, Alain Bayol, Christian Viskov
Journal: Blood (2011)
Administration of Granulocyte Colony-Stimulating Factor Does Not Restore Defective Expression of bcl-2 and bcl-2-xL in Myeloid Progenitor Cells of Patients with Severe Congenital Neutropenia (Kostmann Syndrome).
Authors: Gunnar Cario, Julia Skokowa, Zheng Wang, Vesna Bucan, Cornelia Zeidler, Martin Stanulla, Martin Schrappe, Karl Welte
Journal: Blood (2004)
Etiology of and Associations with Early Death in Adult Patients with Sickle Cell Disease At a Single Referral Institution.
Authors: Courtney Fitzhugh, Darlene Allen, Wynona Coles, Cassie Seamon, Xiongce Zhao, Deepika Darbari, Jonathan Wilson, Meghan Quinn, Matthew Hsieh, Gregory J. Kato, James G. Taylor
Journal: Blood (2012)
Arsenic Trioxide as First Line Therapy for New Case of APL, Results and Long Term Follow up.
Authors: Ardeshir Ghavamzadeh, Kamran Alimoghaddam, Seyed Hamidolah Ghaffari, Shahrbano Rostami, Mohamad Jahani, Seyed Asadollah Mossavi, Massoud Iravani, Ali Khodabandeh, Eissa Baybordi, Babak Bahar, Mahdi Jalili
Journal: Blood (2009)
In vitro evaluation of paclitaxel conjugates with the bicyclic c(RGDfK)2 that target integrin αvβ3
Authors: Claudia Ryppa, Hagit Mann-Steinberg, Ronith Satchi-Fainaro, Felix Kratz
Journal: Cancer Research (2008)

4911  The αvβ3 integrin is overexpressed on proliferating endothelial cells such as those present in growing tumors, as well as on tumor cells of various origins. Tumor-induced angiogenesis can be inhibited in vivo by antagonizing the αvβ3 integrin with small peptides containing the Arg-Gly-Asp (RGD) amino acid sequence. The bicyclic pepide c(RGDfK)2 is a novel ligand-based vascular-targeting agent that binds integrin αvβ3 and demonstrated an uptake of up to 7.5% injected dose/g in OVCAR-3 xenograft tumors. The taxane paclitaxel is a clinically well-established and highly-effective anti-neoplastic medication used as a monotherapy and in combination therapy mainly for the treatment of prostate, breast, ovarian, and non-small cell lung cancer. In this work, we coupled the &2acute;-HO-group of paclitaxel through an aliphatic ester to the amino group of c(RGDfK)2 or the control peptide c(RADfK). Subsequently, we investigated our novel synthetic taxol-derivatives properties using several well-established in vitro angiogenesis assays: Using a standard 72 hours endothelial cell proliferation assay, we showed that both paclitaxel-c(RGDfK)2 and paclitaxel-(RADfK) inhibit the proliferation of HUVEC in a similar manner as free paclitaxel (IC50 value ~0.4 nM). However, a 30 minutes exposure of the cells to the three drugs showed a clear difference between free paclitaxel, paclitaxel-c(RGDfK)2 and paclitaxel-c(RADfK) with IC50 values of 10 nM, 25 nM and 60 nM, respectively. These differences are very likely due to the different routes of cellular entry of these three molecules. While the hydrophobic paclitaxel diffuses rapidly through the cell membrane, the charged peptide-containing derivative paclitaxel-c(RGDfK)2 binds to the overexpressed αvβ3 integrin in order to enter the cells via receptor- mediated endocytosis. The differences between the derivatives were further demonstrated using an endothelial cells adhesion assay. Briefly, HUVEC were incubated with either paclitaxel, paclitaxel-c(RGDfK)2, or paclitaxel-c(RADfK). Free c(RGDfK)2 or c(RADfK) were used as controls. Cells were then allowed to attach on fibrinogen-coated wells. The attached cells were fixed, dyed and their number was quantified. Inhibition of cell attachment was observed only with the paclitaxel-c(RGDfK)2 derivative indicating its specificity to the growing endothelial cells. Furthermore, the paclitaxel derivatives inhibited both endothelial cells migration and capillary-like tube formation. These results further demonstrate their anti-angiogenic properties.
Persistent Clonal Expansion of Vδ3 and Vδ4 T Cells in T-ALL Case with Minimal Residual Disease after HSCT
Authors: Ling Xu, Jianyu Weng, Xin Huang, Shaohua Chen, Suxia Geng, Lijian Yang, Suijing Wu, Suming Huang, Du Xin, Yangqiu Li
Journal: Blood (2014)
Thyroid Function and Its Possible Role in Vascular Degeneration
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Combined Targeting of Chromatin Modifying Enzymes LSD1, EZH2 and Histone Deacetylases (HDACs) Has Superior Efficacy Against Human Mantle Cell Lymphoma Cells
Authors: Warren Fiskus, Sunil Sharma, Rekha Rao, Ramesh Balusu, Sreedhar Venkannagari, Stacey Hembruff, Siddhartha Ganguly, Eduardo M. Sotomayor, Jianguo Tao, David J. Bearss, Kapil N. Bhalla
Journal: Blood (2011)
Analytical method development and pharmacokinetics studies with parthenolide (NSC 157035) and a water-soluble analog (NSC 734325)
Authors: Deping Cheng, Jim J. Xiao, Hao Cheng, Zhongfa Liu, Joseph M. Covey, Kenneth K. Chan
Journal: Cancer Research (2005)

4184  Purpose. Parthenolide (PT, NSC 157035), a sesquiterpene lactone found in extracts of the medicinal plant feverfew (Tanacetum parthenium) used as an herbal medication for a variety of inflammatory diseases, has been found to possess potent cytotoxicity against breast, prostate, pancreas, NSCLC, and bladder tumor cell lines with IC50 values of 1-10 μM. LC-1 (NSC 734325), is a water-soluble analog of parthenolide. The purpose of this study was to develop a highly sensitive LC-MS assay for the analysis of PT and LC-1 in plasma and to characterize their pharmacokinetics in mice. Methods. A triple quadrupole mass spectrometer with electrospray (ESI) ionization was used for quantification. Plasma (0.1 ml) was spiked with PT or LC-1 and the internal standard, hesperetin. The compounds were extracted with ethyl acetate and separated on a BetaBasic C8 column, using isocratic elution. ESI LC-MS/MS with positive ion selected reaction monitor (MRM) mode with ion transitions at m/z 249.4-231.0 and 302.2-302.2 for PT and hesperetin, respectively, was used for PT analysis, while transitions at m/z 294.4-58.0 for LC-1 and 302.2-153.0 for hesperetin were used for LC-1 assay. Assay validation was performed. Pharmacokinetics (PK) of PT in CD1F2 mice was studied following i.v. administration at 4 mg/kg, while PK of LC-1 was studied at 10 mg/kg i.v. Results. Limits of quantification (LOQs) for PT and LC-1 were found to be 2 ng/ml (4.9 nM) and 0.5 ng/ml (1.2 nM), respectively, in mouse plasma. Linearity was demonstrated between LOQ to 1000 ng/ml for both. For PT, the within-day coefficients of variation (CVs) were found to be 13.8%, 8.2%, and 5.6% at 2, 100, and 1000 ng/ml (n=6). For LC-1, the within-day CVs were 7.8%, 6.2%, and 1.4% at 1, 100, and 1000 ng/ml (n=6). The PT between-day CVs were 14.4, 9.1, and 5.5%, respectively, (n=6) and the same respective values for LC-1 were 11.23, 11.28 and 2.3% (n=6). Plasma protein-binding of PT was 75-80% at low μM range. Plasma PT peak levels were ∼0.1 μΜ and levels were detectable for at least 24 h (0.017 μΜ). The broad shape of the AUC and the low and variable plasma levels suggest that PT may have precipitated upon injection and become trapped in vascular beds. In contrast, the PK of LC-1 was found to conform to a two-compartment model with an initial half-life of 22 min and a terminal half-life of 2.87 h. The peak plasma concentration of LC-1 was about 13 μM and levels fell to ∼0.03 μM at 8 h. Total body clearance was 2.8 L/h/kg at 10 mg/kg and protein-binding was 90-92%. Conclusion. The ESI LC-MS/MS was developed and shown useful in quantifying PT and LC-1 in plasma with low nM sensitivity. PT and LC-1 display very different PK behaviors, with the soluble analog producing a larger AUC relative to dose and a smooth biexponential elimination from plasma. In support of RAID Appl 267 (Christopher Sweeney, Indiana University) by NCI-NO1-CM-07019.
Tracking Perfluorocarbon Nanoemulsion Delivery by <sup>19</sup>F MRI for Precise High Intensity Focused Ultrasound Tumor Ablation
Authors: Soo Hyun Shin, Eun-Joo Park, Changki Min, Sun Il Choi, Soyeon Jeon, Yun-Hee Kim, Daehong Kim
Journal: Theranostics (2017)

Perfluorocarbon nanoemulsions (PFCNEs) have recently been undergoing rigorous study to investigate their ability to improve the therapeutic efficacy of tumor ablation by high intensity focused ultrasound (HIFU).For precise control of PFCNE delivery and thermal ablation, their accumulation and distribution in a tumor should be quantitatively analyzed.Here, we used fluorine-19 ( 19 F) magnetic resonance imaging (MRI) to quantitatively track PFCNE accumulation in a tumor, and analyzed how intra-tumoral PFCNE quantities affect the therapeutic efficacy of HIFU treatment.Ablation outcomes were assessed by intra-voxel incoherent motion analysis and bioluminescent imaging up to 14 days after the procedure.Assessment of PFCNE delivery and treatment outcomes showed that 2-3 mg/mL of PFCNE in a tumor produces the largest ablation volume under the same HIFU insonation conditions.Histology showed varying degrees of necrosis depending on the amount of PFCNE delivered. 19F MRI promises to be a valuable platform for precisely guiding PFCNE-enhanced HIFU ablation of tumors.
Utilization and Costs of Deferoxamine in Patients with Thalassemia, Sickle-Cell Disease, or Myelodysplastic Syndrome Receiving Frequent Transfusions.
Authors: Thomas E. Delea, May Hagiwara, Simu K. Thomas, Jean-Francois Baladi, Pradyumna D. Phatak, Thomas D. Coates
Journal: Blood (2005)
Outcome of the Rotterdam-84 CNS-ALL Chemotherapy Protocol without Radiotherapy for Isolated Central Nervous System Relapsed Acute Lymphoblastic Leukemia.
Authors: Auke Beishuizen, Femke K. Aarsen, Jeanette E.W.M. van Dongen, Isabelle C. Streng, Rob Pieters, Karel Hahlen
Journal: Blood (2004)
Robert Willan—Dermatologist and Humanist Extraordinaire
Authors: Richard J. Lucariello
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Myeloma Cell Self-Renewal Depends on JAG2 Expression and Is Mediated by IGF1 or SCF Loop
Authors: David Chiron, Sophie Maiga, Géraldine Descamps, Severine Marionneau, Thilbaud Ouiller, Jerome Moreaux, Bernard Klein, Philippe Moreau, Jean-Luc Harousseau, Regis Bataille, Martine Amiot, Catherine Pellat-Deceunynck
Journal: Blood (2010)
SPAG6 and L1TD1 are transcriptionally regulated by DNA methylation in non-small cell lung cancers
Authors: Corinna Altenberger, Gerwin Heller, Barbara Ziegler, Erwin Tomasich, Maximilian Marhold, Thais Topakian, Leonhard Müllauer, Petra Heffeter, György Lang, Adelheid End-Pfützenreuter, Balazs Döme, Britt-Madeleine Arns, Walter Klepetko, Christoph C. Zielinski, Sabine Zöchbauer-Müller
Journal: Molecular Cancer (2017)

DNA methylation regulates together with other epigenetic mechanisms the transcriptional activity of genes and is involved in the pathogenesis of malignant diseases including lung cancer. In non-small cell lung cancer (NSCLC) various tumor suppressor genes are already known to be tumor-specifically methylated. However, from the vast majority of a large number of genes which were identified to be tumor-specifically methylated, tumor-specific methylation was unknown so far. Thus, the major aim of this study was to investigate in detail the mechanism(s) responsible for transcriptional regulation of the genes SPAG6 and L1TD1 in NSCLCs.We analysed publically available RNA-sequencing data and performed gene expression analyses by RT-PCR. DNA methylation analyses were done by methylation-sensitive high-resolution melt analyses and bisulfite genomic sequencing. We additionally investigated protein expression using immunohistochemistry. Cell culture experiments included tumor cell growth, proliferation, viability as well as colony formation assays. Moreover, we performed xenograft experiments using immunodeficient mice.We observed frequent downregulation of SPAG6 and L1TD1 mRNA expression in primary tumor ﻿(TU) samples compared to corresponding non-malignant lung tissue (NL) samples of NSCLC patients. We furthermore observed re-expression of both genes after treatment with epigenetically active drugs in most NSCLC cell lines with downregulated SPAG6 and L1TD1 mRNA expression. Frequent tumor-specific DNA methylation of SPAG6 and L1TD1 was detected when we analysed TU and corresponding NL samples of NSCLC patients. ROC curve analyses demonstrated that methylation of both genes is able to distinguish between TU and NL samples of these patients. Immunohistochemistry revealed a close association between SPAG6/L1TD1 methylation and downregulated protein expression of these genes. Moreover, by performing functional assays we observed reduced cell growth, proliferation and viability of pCMV6-L1TD1 transfected NSCLC cells. In addition, reduced volumes of tumors derived from pCMV6-L1TD1 compared to pCMV6-ENTRY transfected NCI-H1975 cells were seen in a xenograft tumor model.Overall, our results demonstrate that SPAG6 and L1TD1 are tumor-specifically methylated in NSCLCs and that DNA methylation is involved in the transcriptional regulation of these genes. Moreover, in vitro as well as in vivo experiments revealed tumor-cell growth suppressing properties of L1TD1 in NSCLC cells.